Concord Drugs' Q1 FY 2026-27 Quarterly Results

Result Summary

• Concord Drugs Ltd reported a 44.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 53.9%.
• Its expenses for the quarter were down by 47.8% QoQ and up 44.3% YoY.
• The net profit increased 109.4% QoQ and increased 825.0% YoY.
• The earnings per share (EPS) of Concord Drugs Ltd stood at 0.85 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Concord Drugs Ltd is a company operating in the pharmaceutical industry, primarily engaged in the manufacturing and distribution of pharmaceutical products. The company's portfolio typically includes generic drugs, active pharmaceutical ingredients (APIs), and other healthcare-related products. As of the latest available information, Concord Drugs Ltd has been focusing on expanding its product range and optimizing its production capabilities. However, specific recent major developments about Concord Drugs Ltd are not provided in the data, and therefore, any recent strategic or operational changes within the company remain unspecified.

Revenue

In the first quarter of the fiscal year 2027 (Q1FY27), Concord Drugs Ltd reported a total income of ₹20.95 crores. This represents a significant quarter-over-quarter (QoQ) decline of 44.7% from ₹37.90 crores in the fourth quarter of fiscal year 2026 (Q4FY26). Despite this QoQ decrease, there was a notable year-over-year (YoY) increase of 53.9% compared to the ₹13.61 crores reported in the first quarter of fiscal year 2026 (Q1FY26). These figures reflect the company's revenue trends over the past quarters, showing substantial volatility with a higher income in Q4FY26, followed by a drop in Q1FY27, though still maintaining growth compared to the previous year's same quarter.

Profitability

The company reported a profit before tax (PBT) of ₹1.54 crores in Q1FY27, which shows a significant improvement both QoQ and YoY. The QoQ increase from ₹0.75 crores in Q4FY26 stands at 105.3%, while the YoY increase is an impressive 862.5% from the ₹0.16 crores in Q1FY26. After accounting for taxes, the profit after tax (PAT) for Q1FY27 was ₹1.11 crores, marking a QoQ rise of 109.4% from ₹0.53 crores in Q4FY26 and a YoY rise of 825.0% from ₹0.12 crores in Q1FY26. The earnings per share (EPS) followed a similar trajectory, with a QoQ rise of 80.9% and a YoY increase of 608.3%, indicating enhanced profitability for the shareholders during this period.

Operating Metrics

Total expenses for Concord Drugs Ltd in Q1FY27 were ₹19.41 crores, which decreased by 47.8% QoQ from ₹37.15 crores in Q4FY26. Despite this reduction in expenses, there was an increase of 44.3% YoY from ₹13.45 crores in Q1FY26. These changes in expense levels are significant and highlight the company's operational cost management over the periods. The tax expense for Q1FY27 was ₹0.43 crores, up 95.5% QoQ from ₹0.22 crores in Q4FY26 and 975.0% YoY from ₹0.04 crores in Q1FY26. This increase in tax expenses is consistent with the rise in profitability. The financial metrics provided indicate significant shifts in Concord Drugs Ltd's operational costs and tax liabilities, reflecting broader trends in its financial management and operational efficiency.